Anti-C6 Antibodies for Complement Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective reagents to inhibit C6, a component of the complement system, which is involved in various diseases including neurodegenerative disorders and multiple sclerosis.
Innovation Solution
Development of anti-C6 antibodies with specific functional properties, such as high affinity, long half-life, and ability to inhibit membrane attack complex formation, both in vitro and in vivo.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used, then treatment of complement-mediated diseases is provided, but effective reagents to inhibit C6 are lacking
Solution Approach 1:
The patent creates artificial C6 proteins containing mutated cysteine residues that can be engineered to form disulfide bonds with specific antibodies. This copying approach involves designing synthetic variants of the natural C6 protein that retain functional activity while enabling controlled antibody binding, thereby creating reliable therapeutic reagents where none effectively existed before
Solution Approach 2:
The patent systematically modifies the C6 protein by mutating specific cysteine residues to serine or alanine, or by introducing new cysteine residues at defined positions. These parameter changes in the protein structure enable controlled disulfide bond formation with antibodies, creating a library of C6 variants with different antibody binding characteristics for optimized therapeutic inhibition
2Reliability
If anti-C6 antibodies are developed with high affinity, then inhibition of C6 functional activity is improved, but antibody development complexity increases
Solution Approach 1:
The patent performs preliminary engineering of the C6 protein by introducing or mutating cysteine residues at specific positions before antibody generation. This preliminary action creates predetermined binding sites on C6 that guide the development process, allowing systematic screening of antibody candidates against defined epitopes rather than searching the entire antibody space, thereby reducing overall development complexity while achieving high-affinity inhibition
Solution Approach 2:
The patent divides the C6 protein into functional segments by focusing on specific cysteine residues as discrete binding epitopes. By mutating individual cysteines or introducing them at specific positions, the patent segments the antibody binding problem into manageable epitope-specific developments, allowing parallel optimization of multiple antibody candidates targeting different segments of C6
3Duration of action of stationary object
If antibodies with long half-life are engineered, then therapeutic duration is extended, but antibody design complexity increases
Solution Approach 1:
The patent employs self-service approaches by using the C6 protein's own structural features (cysteine residues) to create the binding interface. The engineered C6 variants present specific cysteine thiol groups that automatically form disulfide bonds with antibody light chain CDR regions, creating stable complexes. This self-organizing binding mechanism reduces the need for complex antibody engineering to achieve long half-life, as the stability emerges from the inherent chemistry of disulfide bond formation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-C6 antibodies effectively inhibit C6 functional activity, providing therapeutic potential for disorders mediated by the complement system, including neurodegenerative diseases and multiple sclerosis.
Implementation Method 1
anti-C6 antibodies that bind human C6 and exhibit at least three of the following properties: (a) has an IC50 in a haemolytic assay of 0.5 μg/ml or less; (b) has a KD, as determined by surface plasmon resonance, of 1×10−8 M or less
Data Source
AI summary
Isolated monoclonal antibodies that bind to human complement component C6 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic methods for using the antibodies.